Get started
Author

Daisy C. M. Lam

Observed names: Daisy C M Lam, Daisy C.M. Lam, Daisy CM Lam, Daisy CM. Lam, Daisy Chor Man Lam, Daisy Lam
ORCID: 0000-0002-7246-6550
Observed ORCID: 0000-0002-7246-6550
OpenAlex ID: A5113976996
Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
2016 · Darren M. C. Poon, Kuen Chan, et al. · BMC Urology · 49
PDF
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients
2020 · Winnie Yeo, Thomas KH. Lau, et al. · The Breast · 44
PDF
Dynamic Changes of Post-Radiotherapy Plasma Epstein–Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer
2021 · Edwin Pun Hui, Brigette B.Y. Ma, et al. · Clinical Cancer Research · 29
Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone‐naïve prostate cancer: The first real‐life experience in Asia
2018 · Darren M. C. Poon, Tim Chan, et al. · Asia-Pacific Journal of Clinical Oncology · 19
PDF
Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer
2018 · Stephen L. Chan, Anthony W.H. Chan, et al. · The Oncologist · 18
PDF
NEOSPACE trial: Neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC).
2023 · Edwin P Hui, Brigette Ma, et al. · Journal of Clinical Oncology · 15
Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer
2022 · Darren M. C. Poon, Kuen Chan, et al. · Cancers · 13
PDF
Treatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy
2025 · Darren M. C. Poon, William S. K. Cheung, et al. · Frontiers in Oncology · 11
Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study
2017 · Darren M.C. Poon, Kuen Chan, et al. · Prostate International · 10
PDF
Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer
2021 · Darren M. C. Poon, Daisy Lam, et al. · Current Oncology · 7
PDF
A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer
2018 · Jeremy Y.C. Teoh, Darren M.C. Poon, et al. · Clinical Genitourinary Cancer · 7
Health-related quality of life of glioblastoma patients receiving post-operative concomitant chemoradiotherapy plus adjuvant chemotherapy: A longitudinal study
2021 · Kai-Fung Kevin Suen, Danny Tat Ming Chan, et al. · Interdisciplinary Neurosurgery · 5
PDF
Patient Preference of Apalutamide Versus Enzalutamide for Recurrent or Metastatic Hormone-sensitive Prostate Cancer: An Open-label, Randomized, Crossover Trial
2024 · Chi-Fai Ng, Chi-Hang Yee, et al. · European Urology Oncology · 4
Clinical outcome of neoadjuvant chemoradiation in locally advanced rectal cancer at a tertiary hospital
2016 · William WK Yeung, Brigette BY Ma, et al. · Hong Kong Medical Journal · 4
Risks and impacts of thromboembolism in patients with pancreatic cancer
2023 · Landon L Chan, KY Lam, et al. · Hong Kong Medical Journal · 3
PDF
EUS-guided fiducial marker insertion for radiotherapy in advanced esophageal carcinoma: submucosal insertion may lead to less migration when compared to intratumoral insertion
2021 · Shannon Melissa Chan, Teresa Tse, et al. · Surgical Endoscopy · 2
Acute Toxicity and Quality of Life With Stereotactic Body Radiation Therapy Versus Conventional Fractionated Intensity Modulated Radiation Therapy to the Prostate and Pelvis in High-Risk Prostate Cancer: A Randomized Phase 2 Trial
2026 · Darren M.C. Poon, Kenneth Wong, et al. · International Journal of Radiation Oncology*Biology*Physics · 1
Prognostic implication of the neoadjuvant rectal score and other biomarkers of clinical outcome in Hong Kong Chinese patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy
2022 · Sandy SK Ho, Sophie SF Hon, et al. · Hong Kong Medical Journal · 1
PDF
Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for patients with early-stage localized prostate cancer: One-year late toxicity results from a prospective randomized phase II study.
2019 · Darren M.C. Poon, Daisy Lam, et al. · Journal of Clinical Oncology · 1
The association between serum folate level and toxicity of capecitabine.
2016 · Stephen Lam Chan, Brigette Ma, et al. · Journal of Clinical Oncology · 1
Pembrolizumab in advanced acral lentiginous melanoma: final results of a single-centre, open-label, phase II trial in an East Asian population
2026 · Herbert H. Loong, Winnie Yeo, et al. · medRxiv
PDF
Impact of Antibiotic Use in the Primary Treatment of Nasopharyngeal Carcinoma
2026 · Bojie Chen, Whitney T. Y. Ngan, et al. · Cancers
PDF
Comparative real-world analysis of stereotactic body radiotherapy versus conventional radiotherapy for Chinese patients with low- to intermediate-risk localised prostate cancer
2026 · Benjamin HW Lam, Eric KH Chan, et al. · Hong Kong Medical Journal
PDF
Multicenter phase II study of neoadjuvant FOLFOXIRI followed by concurrent chemoradiotherapy in Chinese patients with high-risk rectal cancer
2026 · Rashid N Lui, Simon Chu, et al. · The Oncologist
Radiation-induced lymphopenia is associated with survival in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy
2025 · Landon L. Chan, Vanessa T.Y. Yeung, et al. · JHEP Reports
PDF
Works count: 35
Citation count: 244
H-index: 9
I10-index: 9
Year
Topic
Type